MX2010005866A - Una composicion farmaceutica para tratar una enfermedad relacionada con la obesidad que comprende conjugado de peptido insulinotropico. - Google Patents

Una composicion farmaceutica para tratar una enfermedad relacionada con la obesidad que comprende conjugado de peptido insulinotropico.

Info

Publication number
MX2010005866A
MX2010005866A MX2010005866A MX2010005866A MX2010005866A MX 2010005866 A MX2010005866 A MX 2010005866A MX 2010005866 A MX2010005866 A MX 2010005866A MX 2010005866 A MX2010005866 A MX 2010005866A MX 2010005866 A MX2010005866 A MX 2010005866A
Authority
MX
Mexico
Prior art keywords
treating obesity
related diseases
insulinotropic peptide
peptide conjugate
pharmaceutical composition
Prior art date
Application number
MX2010005866A
Other languages
English (en)
Inventor
Se Chang Kwon
Dae Hae Song
Sung Youb Jung
Gwan Sun Lee
Min Young Kim
Young Jin Park
Eun Hee Kang
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/947,697 external-priority patent/US20090238838A1/en
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MX2010005866A publication Critical patent/MX2010005866A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a una composición para tratar enfermedades relacionadas con la obesidad que comprende un conjugado de péptido insulinotrópico, más particularmente, a una composición para tratar enfermedades relacionadas con la obesidad que comprende un conjugado preparado por el enlace covalente del péptido insulinotrópico con una sustancia portadora por medio de un enlazador no peptidílico, y un método para tratar enfermedades relacionadas con la obesidad al utilizar el mismo;; en particular, la composición para tratar enfermedades relacionadas con la obesidad de acuerdo con la presente invención mejora de manera notable la eficacia de suprimir la ingesta de alimento y su duración para reducir el peso corporal, la grasa corporal, con lo cual es útil para el tratamiento de enfermedades relacionadas con la obesidad.
MX2010005866A 2007-11-29 2008-11-28 Una composicion farmaceutica para tratar una enfermedad relacionada con la obesidad que comprende conjugado de peptido insulinotropico. MX2010005866A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/947,697 US20090238838A1 (en) 2003-11-13 2007-11-29 Insulinotropic peptide conjugate using an immunoglobulin fc
KR1020080083194A KR101135244B1 (ko) 2007-11-29 2008-08-26 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
PCT/KR2008/007074 WO2009069983A2 (en) 2007-11-29 2008-11-28 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate

Publications (1)

Publication Number Publication Date
MX2010005866A true MX2010005866A (es) 2010-06-23

Family

ID=40988127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005866A MX2010005866A (es) 2007-11-29 2008-11-28 Una composicion farmaceutica para tratar una enfermedad relacionada con la obesidad que comprende conjugado de peptido insulinotropico.

Country Status (22)

Country Link
EP (1) EP2227243B1 (es)
JP (1) JP5226080B2 (es)
KR (1) KR101135244B1 (es)
CN (1) CN101878036B (es)
AR (1) AR069458A1 (es)
AU (1) AU2008330315B2 (es)
BR (1) BRPI0819864A2 (es)
CA (1) CA2706627C (es)
DK (1) DK2227243T3 (es)
ES (1) ES2521497T3 (es)
HK (1) HK1150029A1 (es)
HR (1) HRP20140997T1 (es)
IL (1) IL205667A (es)
MX (1) MX2010005866A (es)
MY (1) MY155454A (es)
NZ (1) NZ585314A (es)
PL (1) PL2227243T3 (es)
PT (1) PT2227243E (es)
RU (1) RU2446816C2 (es)
TW (1) TWI403331B (es)
WO (1) WO2009069983A2 (es)
ZA (1) ZA201003796B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
ES2692187T3 (es) * 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
KR101577734B1 (ko) * 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR101350824B1 (ko) * 2011-12-14 2014-01-13 서울대학교산학협력단 리파아제 특이적 지질-펩타이드 기질 라이브러리 및 이를 이용한 리파아제 저해제를 유효성분으로 함유하는 비만 및 지질대사 이상 관련 질환의 치료 및 예방용 약학적 조성물
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN102580087B (zh) * 2012-03-08 2013-08-21 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
MX362432B (es) * 2012-06-04 2019-01-17 Opko Biologics Ltd Variantes de oxm pegilada.
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
RU2677800C2 (ru) * 2013-02-26 2019-01-21 Ханми Фарм. Ко., Лтд. Сайт-специфичный конъюгат инсулина
JP6374412B2 (ja) * 2013-03-05 2018-08-15 ハンミ ファーム．カンパニー リミテッドＨａｎｍｉ Ｐｈａｒｍ．Ｃｏ．，Ｌｔｄ． 生理活性ポリペプチド結合体の高収率生産のための改善された製造方法
CN104086655B (zh) * 2013-04-02 2019-02-15 常州博闻迪医药科技有限公司 胰淀素样融合蛋白及其编码基因与应用
WO2014161835A1 (en) * 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016196017A1 (en) 2015-06-04 2016-12-08 Antriabio, Inc. Amine pegylation methods for the preparation of site-specific protein conjugates
CA3086918A1 (en) * 2018-01-03 2019-07-11 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of nash and other disorders
CN113181346A (zh) * 2018-03-09 2021-07-30 上海仁会生物制药股份有限公司 用于治疗肥胖和体重管理的glp-1组合物
KR102193211B1 (ko) * 2019-11-27 2020-12-18 (주)디앤디파마텍 비오틴 모이어티가 결합된 폴리펩티드 및 이를 포함하는 경구 투여용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
TR199802789T2 (xx) * 1996-06-05 1999-03-22 Boehringer Mannheim Gmbh Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
DK1019077T4 (da) * 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
CZ306180B6 (cs) * 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
JP4870569B2 (ja) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
ITPD20050253A1 (it) * 2005-08-16 2007-02-17 Sit La Precisa Spa Dispositivo per il controllo multifunzionale dell'erogazione di un gas combustibile verso un apparecchio bruciatore
US20100021480A1 (en) * 2005-10-27 2010-01-28 Peptron Co., Ltd Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体

Also Published As

Publication number Publication date
EP2227243A2 (en) 2010-09-15
WO2009069983A3 (en) 2009-08-20
PT2227243E (pt) 2014-10-22
CA2706627A1 (en) 2009-06-04
MY155454A (en) 2015-10-15
JP2011505355A (ja) 2011-02-24
IL205667A0 (en) 2010-11-30
NZ585314A (en) 2012-10-26
ZA201003796B (en) 2011-02-23
EP2227243B1 (en) 2014-08-13
KR20090056796A (ko) 2009-06-03
CN101878036B (zh) 2014-05-14
HRP20140997T1 (hr) 2014-12-19
KR101135244B1 (ko) 2012-04-24
TWI403331B (zh) 2013-08-01
RU2446816C2 (ru) 2012-04-10
CA2706627C (en) 2014-11-18
TW200936154A (en) 2009-09-01
DK2227243T3 (da) 2014-10-06
AR069458A1 (es) 2010-01-20
HK1150029A1 (en) 2011-10-28
CN101878036A (zh) 2010-11-03
BRPI0819864A2 (pt) 2017-05-23
AU2008330315B2 (en) 2012-06-21
PL2227243T3 (pl) 2015-03-31
JP5226080B2 (ja) 2013-07-03
IL205667A (en) 2016-11-30
WO2009069983A2 (en) 2009-06-04
RU2010126478A (ru) 2012-01-10
EP2227243A4 (en) 2012-05-09
AU2008330315A1 (en) 2009-06-04
ES2521497T3 (es) 2014-11-12

Similar Documents

Publication Publication Date Title
MY155454A (en) A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MX2007012702A (es) Uso de anticuerpos cd25 en inmunoterapia.
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
MY148246A (en) Bicyclic amides as kinase inhibitors
PH12018501119A1 (en) A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
WO2007128817A3 (en) Insulin derivative
MX2018006844A (es) Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
EA033415B1 (ru) Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
NZ606480A (en) Albumin binding peptide-mediated disease targeting
MX2009006541A (es) Tratamiento de prdc en cerdos.
EP2949344A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
TN2009000213A1 (en) Combination
EP1948214A4 (en) ANTI-TNF-ALPHA TREATMENT FOR TREATING ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY TREATMENT
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2006128125A3 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
WO2008126587A1 (ja) 抗疲労剤
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
WO2007104768A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2007144889A3 (en) Treatment of neurofibromatosis
WO2009111273A3 (en) Peptide targeting imaging agents and methods of use thereof
TH137153A (th) องค์ประกอบทางเภสัชศาสตร์สำหรับการรักษาโรคอันเกิดจากภาวะความอ้วนเกินปกติประกอบด้วยคู่อินซูลิโนโทรปิค เพปไทด์
WO2008049424A3 (de) Pharmazeutische zusammensetzung zur behandlung allergischer erkrankungen
佐藤雅樹 Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: HANMI SCIENCE CO., LTD.*

HC Change of company name or juridical status

Owner name: HANMI SCIENCE CO., LTD.*

FG Grant or registration